BioNTech Burns Through €532 Million as Factory Closures and Founder Departure Mark End of COVID Era

BioNTech posts €118M Q1 revenue and €532M net loss, cuts 1,860 jobs, and closes four sites to fund 15 Phase 3 oncology trials targeting ten cancer indications by 2030.

The numbers tell a brutal story of transition. BioNTech’s first-quarter revenue slumped to €118 million, a 35% year-on-year decline, while the net loss ballooned to €532 million — roughly €116 million deeper than the same period last year. Yet behind the red ink lies a deliberate strategy: the Mainz-based biotech is torching its pandemic-era infrastructure to fund a future in oncology.

The COVID vaccine business, which once generated billions in quarterly revenue, is now a seasonal afterthought. CFO Ramon Zapatero described the first-quarter performance as “saisonbedingt und plangemäß” — seasonal and on plan. The company is sticking to its full-year revenue forecast of €2.0 to €2.3 billion, though the bulk of that will arrive in the second half. A €613 million payment from the VMS collaboration is expected to land in the third quarter, providing a significant jolt to the top line.

Factory closures and 1,860 job cuts

BioNTech is shrinking its manufacturing footprint with surgical precision. Four production sites — Idar-Oberstein, Marburg, Tübingen, and Singapore — are slated for closure by the end of 2027, with Singapore shutting its doors as early as the first quarter of that year. The move will eliminate roughly 1,860 positions, or about 22% of the global workforce. COVID vaccine production is being handed over entirely to Pfizer.

The cost savings are substantial: by 2029, BioNTech expects to generate annual recurring savings of around €500 million. That freed-up capital is being redirected into the oncology pipeline, which now boasts 15 active Phase 3 trials. The company’s ambition is to secure approvals for ten cancer indications by 2030.

Research spending hit €557 million in the quarter, driven by the lead candidates Pumitamig and Gotistobart. Pumitamig alone entered five new registration studies in the first quarter, targeting breast, colorectal, gastric, and lung cancers. Gotistobart delivered striking Phase 3 data: after twelve months, 25% of treated patients showed no disease progression, compared to zero in the docetaxel control group. The risk of death fell by 54%, though management cautioned that the sample size remains small. Meanwhile, the HER2-directed antibody-drug conjugate Trastuzumab Pamirtecan posted a confirmed response rate of 49% in endometrial cancer.

Founders exit, buyback begins

The most dramatic change is at the top. Co-founders Ugur Sahin and Özlem Türeci plan to step down from their operational roles by the end of 2026 to launch a new venture focused on early-stage mRNA research. The supervisory board has begun searching for successors, a process that coincides with the planned market entry of BioNTech’s first cancer immunotherapies.

Investors have reacted with skepticism. The stock fell roughly 4% on the day of the quarterly report and closed the week at €79.45 — about 10% below the prior week’s level and roughly 9% below its 200-day moving average. The shares are trading well below the 50-day average of €83.

To counter the uncertainty, the board approved a share buyback program on May 7 worth up to $1 billion in American Depositary Shares, running through May 2027. That represents roughly 4.2% of outstanding shares and will be funded from the company’s cash pile, which stood at €16.8 billion at the end of the quarter.

Analysts remain broadly bullish. The median price target sits at $131.65 per ADS, well above current levels. Whether that valuation holds depends on two variables: a smooth leadership transition and timely oncology approvals. With several Phase 3 readouts still expected this year, the next few months will be decisive.